Clinical Trial Detail

NCT ID NCT03990896
Title Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

triple-receptor negative breast cancer

Her2-receptor negative breast cancer

Therapies

Talazoparib

Age Groups: adult senior

No variant requirements are available.